Christensen group: Cellular and molecular biology of myocardial hypertrophy

Christensen group

We aim to develop novel therapeutic approaches and better diagnostic tools for heart failure through new knowledge about molecular mechanisms involved.

 

 

In particular, we study the concept that cardiac proteoglycans are active and central signal mediators of myocardial remodeling. Proteoglycans are highly glycosylated proteins localized to the cell membranes and the extracellular matrix (ECM).

By examining the unique properties of transmembrane proteoglycans we have discovered that the proteoglycan syndecan-4 is a mechanical stress-sensor in cardiomyocytes and cardiac fibroblasts and involved in signalling causing heart failure. One important ECM-localized molecule is lumican and we have shown that it regulates cardiac remodelling and heart failure. Currently we are testing promising drugs to treat heart failure by targeting mechanisms identified by our group. The ultimate goal of our research is to improve the well-being and prognosis of patients.

 

The work in this group is supervised by professor Geir Christensen. The group consists of scientists from IEMR that collaborate closely with Department of Thoracic Surgery (Professor Theis Tønnessen) and Department of Cardiology at Oslo University Hospital (Professor Lars Gullestad). In addition to top-of-the-range international scientists from Harvard, Johns Hopkins, among others, who are world leading in their field.

Group Leader

Geir Christensen

Group Leader & Professor

Group members

Andreas Romaine

Postdoctoral fellow

Athiramol Sasi

Doctoral Research Fellow

Camilla Udjus

Doctoral Research Fellow

Chloe Rixon

Doctoral Research Fellow

Francesca Lockwood

Doctoral Research Fellow

Mari Elen Strand

Postdoctoral fellow

Maria Vistnes

Postdoctoral fellow, Resident

Latest publications

view all >
Støle TP, Lunde M, Shen X, Martinsen M, Lunde PK, Li J, Lockwood F, Sjaastad I, Louch WE, Aronsen JM, Christensen G, Carlson CR (2022)
The female syndecan-4-/- heart has smaller cardiomyocytes, augmented insulin/pSer473-Akt/pSer9-GSK-3β signaling, and lowered SCOP, pThr308-Akt/Akt and GLUT4 levels
Front Cell Dev Biol, 10, 908126
PubMed 36092718 DOI 10.3389/fcell.2022.908126
Andreassen K, Dejgaard LA, Lie Ø, Fink TS, Lunde IG, Edvardsen T, Haugaa KH, Stokke MK (2022)
Exercise training during childhood and adolescence is associated with favorable diastolic function in hypertrophic cardiomyopathy
Int J Cardiol, 364, 65-71
PubMed 35714718 DOI 10.1016/j.ijcard.2022.06.042
Romaine A, Melleby AO, Alam J, Lobert VH, Lu N, Lockwood FE, Hasic A, Lunde IG, Sjaastad I, Stenmark H, Herum KM, Gullberg D, Christensen G (2022)
Integrin α11β1 and syndecan-4 dual receptor ablation attenuate cardiac hypertrophy in the pressure overloaded heart
Am J Physiol Heart Circ Physiol, 322 (6), H1057-H1071
PubMed 35522553 DOI 10.1152/ajpheart.00635.2021
Berge K, Brynildsen J, Røysland R, Strand H, Christensen G, Høiseth AD, Omland T, Røsjø H, Lyngbakken MN (2022)
Prognostic value of cardiac biomarkers and National Early Warning Score 2 in acute dyspnoea
Open Heart, 9 (1)
PubMed 35387863 DOI 10.1136/openhrt-2021-001938
Gløersen M, Steen Pettersen P, Neogi T, Jafarzadeh SR, Vistnes M, Thudium CS, Bay-Jensen AC, Sexton J, Kvien TK, Hammer HB, Haugen IK (2022)
Associations of Body Mass Index With Pain and the Mediating Role of Inflammatory Biomarkers in People With Hand Osteoarthritis
Arthritis Rheumatol, 74 (5), 810-817
PubMed 35137553 DOI 10.1002/art.42056
view all >